Author

Gudrun Pregartner

Medical University of GrazORCID 0000-0002-9899-0502Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Akshaya Kailasnathan· 2 shared Andreas ReinischiD· 2 shared Annkristin HeineiD· 2 shared Armin ZebischiD· 2 shared Bianca PerfleriD· 2 shared Eva Gruden· 2 shared Gerald HöefleriD· 2 shared Heinz SilliD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Akshaya Kailasnathan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EZH2 inactivation drives MAPK-dependent vulnerability to MEK inhibition in RAS-mutant CMML

Eva Gruden, Bianca Perfler, Akshaya Kailasnathan, Panagiota Chaida, KARIN LIND, Marie-Christina Mayer, Johannes Foßelteder, Melanie Kienzl, Sayantanee Dutta, Sonja Wurm, Jennifer Neiss, Katarina Vizar Cisarova, Gerald Höefler, Karl Kashofer, Klaus Geissler, , Armin Zebisch

This study identifies RASmutEZH2inact as a distinct CMML subgroup with increased MEK inhibitor sensitivity due to MAPK/ERK hyperactivation.

bioRxiv · Jun 4, 2026 · PreprintMolecular Biology

RAS-mutant clones drive extramedullary acute myeloid leukemia

Panagiota Chaida, Julia Frimmel, Lara Hopfer, Bianca Perfler, Eva Gruden, Akshaya Kailasnathan, KARIN LIND, Bernadette Bramreiter, Johannes Foßelteder, Sonja Wurm, Jennifer Neiss, Stefan Koeck, Dominik Georg Friedrich Wolf, Gudrun Ratzinger, Nassim Ghaffari‐Tabrizi‐Wizsy, , Armin Zebisch

This study identifies RAS mutations as a key driver of extramedullary acute myeloid leukemia, showing their role in promoting leukemic cell migration and infiltration through the JAML-PI3K/AKT pathway.

bioRxiv · Apr 9, 2026 · PreprintCancer Biology